Audit: The use of radiotherapy for NSCLC in the UK

Maher, E.J.; Timothy, A.R.; Squire, C.J.; Goodman, Alice; Karp, S.J.; Paine, C.H.; Ryall, R. D. H.; Read, G.

doi:10.1016/s0936-6555(05)80850-7

Cited by 51 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although CHART was used infrequently (8% of patients), 55 Gy/20 fractions was the most commonly used regimen. As in previous studies [5,23] we conclude that 55 Gy/20 fractions has been widely adopted across the UK. This regimen has not been formally tested against 2 Gy per fraction alternatives.…”

Section: Discussionsupporting

confidence: 87%

The Quality of Curative-intent Radiotherapy for Non-small Cell Lung Cancer in the UK

McAleese¹,

Baluch²,

Drinkwater³

2015

Clinical Oncology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 87%

The Quality of Curative-intent Radiotherapy for Non-small Cell Lung Cancer in the UK

McAleese¹,

Baluch²,

Drinkwater³

2015

Clinical Oncology

View full text Add to dashboard Cite

“…Radiotherapy plays a major role in lung cancer management ( Baker et al, 2016 ). This role ranges from curative intent as component of concurrent chemo-radiotherapy for stage III disease and stereotactic ablative body (SABR) radiotherapy for early stage NSCLC to palliative intent for advanced stage for pain and hemoptysis ( Maher et al, 1993 ). Delay in radiotherapy more than 24 days associated with a risk up to 30 % of disease progression for NSCLC patients mainly stage III disease ( Everitt et al, 2010 ).…”

Section: Implication Of Covid-19 On Radiotherapymentioning

confidence: 99%

Implications of COVID-19 pandemic on lung cancer management: A multidisciplinary perspective

Bakhribah

Zeitouni

Daghistani

et al. 2020

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Treatment of patients with lung cancer during the current COVID-19 pandemic is challenging. Lung cancer is a heterogenous disease with a wide variety of therapeutic options. Oncologists have to determine the risks and benefits of modifying the treatment plans of patients especially in situation where the disease biology and treatment are complex. Health care visits carry a risk of transmission of SARS-CoV-2 and the similarities of COVID-19 symptoms and lung cancer manifestations represent a dominant problem. Efforts to modify treatment of lung cancer during the current pandemic have been adapted by many healthcare institutes to reduce exposure of lung cancer patients to SARS-CoV-2. We summarized the implications of COVID-19 pandemic on the management of lung cancer from the perspective of different specialties of thoracic oncology multidisciplinary team.

show abstract

“…Palliative thoracic radiotherapy is a cornerstone of Radiation Oncology practice, with older estimates from the UK perspective suggesting that 20-25 % of a typical Radiation Oncologist's practice deals with lung-related issues, and 90 % of these treatments are palliative in nature [3]. Initially, fractionation schemes for palliative thoracic radiotherapy in stage IV NSCLC were largely developed empirically, and were subjected to more rigorous clinical trial evaluation in the 1980s and 1990s.…”

Section: External-beam Radiotherapymentioning

confidence: 99%

A review of palliative radiotherapy for lung cancer and lung metastases

et al. 2012

View full text Add to dashboard Cite

Introduction Treatment of thoracic symptoms related to lung cancer with palliative radiotherapy is routinely performed in conjunction with radiation oncology practice. Various clinical trials, meta-analyses, practice guidelines, consensus statements, and Cochrane reviews have been conducted on different questions related to palliative thoracic radiotherapy considerations including: patient selection, external-beam radiotherapy dose fractionation, endobronchial brachytherapy, and chemotherapy. Discussion Novel radiotherapy technologies such as stereotactic ablative radiotherapy may allow new populations to benefit from radiotherapy. These new populations include: early stage lung cancer patients not fit for surgery that previously would be treated with best supportive care or palliative approaches and the treatment of oligometastatic lung metastases. ConclusionThe goal of this narrative review is: (1) to review the foundations of what has already been established in palliative thoracic radiotherapy, with a focus on published clinical trials, (2) to review and discuss emerging data and trends in radiotherapeutic options for patients with advanced thoracic malignancies, with a focus on both clinical trials and other forms comparative-effectiveness research, and (3) to discuss active areas of research and future directions for research in this challenging patient population.

show abstract

Audit: The use of radiotherapy for NSCLC in the UK

Cited by 51 publications

References 17 publications

The Quality of Curative-intent Radiotherapy for Non-small Cell Lung Cancer in the UK

The Quality of Curative-intent Radiotherapy for Non-small Cell Lung Cancer in the UK

Implications of COVID-19 pandemic on lung cancer management: A multidisciplinary perspective

A review of palliative radiotherapy for lung cancer and lung metastases

Contact Info

Product

Resources

About